Improvement of proportion of days covered for denosumab under implementation of clinical pharmacist adherence management system: normal and COVID-19 period
Description
CONCLUSIONS: Clinical pharmacist-led CPAMS could effectively improve adherence to denosumab and the treatment of osteoporosis.
